Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 12/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157109 | 0.85 | PARP1 (0.44) | CHKALSSACVR1 | |
| SCHEMBL3725925 | 0.84 | MC4R (0.47) | CHKAMC4R | |
| SCHEMBL4161690 | 0.83 | HRH3 (0.64) | LMNALSSPRMT6ALDH1A1 | |
| SCHEMBL3728567 | 0.78 | CHEK1 (0.52) | CHKATGFBR1ACVR1ALDH1A1 | |
| SCHEMBL3725982 | 0.78 | HRH3 (0.42) | LSSALDH1A1 | |
| SCHEMBL13815493 | 0.77 | CLK2 (0.41) | LSS | |
| SCHEMBL3140527 | 0.77 | CHKA (0.70) | CHKALMNAMC4RCA2NCF1 | |
| SCHEMBL3142344 | 0.77 | CHKA (0.62) | CHKALMNAMC4RCA2NCF1 | |
| SCHEMBL4161695 | 0.76 | HDAC1 (0.45) | — | |
| SCHEMBL11992681 | 0.76 | CHKA (0.59) | CHKALMNAMC4RLSSTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CHKA 3977/4885LMNA 2708/4885MC4R 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.